



CITY OF DORAL NOTICE OF PUBLIC HEARING

All residents, property owners and other interested parties are hereby notified of a **Council Zoning Hearing** on **Wednesday, May 24, 2017, beginning at 6:00 PM** to establish an eight (8) month moratorium on the application of the City of Doral Workforce Housing Program, codified in Section 74-886-893 of the Land Development Code. The City Council will consider this item for <u>SECOND READING</u>. This meeting will be held at the **City of Doral, Government Center, Council Chambers located at 8401** NW 53rd Terrace, Doral, Florida 33166.

The City of Doral proposes to adopt the following Ordinance:

ORDINANCE No. 2017-07


AN ORDINANCE OF THE MAYOR AND THE CITY COUNCIL OF THE CITY OF DORAL, FLORIDA, APPROVING/DENYING THE ESTABLISHMENT OF AN EIGHT-MONTH MORATORIUM ON THE APPLICATION OF THE CITY OF DORAL WORKFORCE HOUSING PROGRAM, CODIFIED IN SECTION 74-886-893 OF THE LAND DEVELOPMENT CODE; PROVIDING FOR CONFLICTS; PROVIDING FOR SEVERABILITY; AND PROVIDING FOR AN EFFECTIVE DATE

HEARING NO.: 17-05-DOR-07

APPLICANT: City of Doral

REQUEST: The City of Doral (The "Applicant") is requesting Mayor and City Council approval to establish an eight (8)-month moratorium on the application of the City of Doral Workforce Housing Program, codified in Section 74-886-893 of the Land Development Code.

Location Map



Information relating to this request is on file and may be examined in the City of Doral, Planning and Zoning Department located at **8401 NW 53rd Terrace, Doral, Fl. 33166.** All persons are invited to appear at this meeting or be represented by an agent, or to express their views in writing addressed to the City Clerk, **8401 NW 53rd Terrace, Doral, Fl. 33166.** Maps and other data pertaining to these applications are available for public inspection during normal business hours in City Hall. Any persons wishing to speak at a public hearing should register with the City Clerk prior to that item being heard. Inquiries regarding the item may be directed to the Planning and Zoning Department at 305-59-DORAL.

Pursuant to Section 286.0105, Florida Statutes If a person decides to appeal any decisions made by the City Council with respect to any matter considered at such meeting or hearing, they will need a record of the proceedings and, for such purpose, may need to ensure that a verbatim record of the proceedings is made, which record includes the testimony and evidence upon which the appeal is to be based. This notice does not constitute consent by the City for introduction or admission of otherwise inadmissible or irrelevant evidence, nor does it authorize challenges or appeals not otherwise allowed by law. In accordance with the Americans with Disabilities Act, all persons who are disabled and who need special accommodations to participate in this meeting because of that disability should contact the Planning and Zoning Department at 305-59-DORAL no later than three (3) business days prior to the proceeding.

NOTE: If you are not able to communicate, or are not comfortable expressing yourself, in the English language, it is your responsibility to bring with you an English-speaking interpreter when conducting business at the City of Doral during the zoning application process up to, and including, appearance at a hearing. This person may be a friend, relative or someone else. A minor cannot serve as a valid interpreter. The City of Doral DOES NOT provide translation services during the zoning application process or during any quasi-judicial proceeding.

NOTA: Si usted no está en capacidad de comunicarse, o no se siente cómodo al expresarse en inglés, es de su responsabilidad traer un intérprete del idioma inglés cuando trate asuntos públicos o de negocios con la Ciudad de Doral durante el proceso de solicitudes de zonificación, incluyendo su comparecencia a una audiencia. Esta persona puede ser un amigo, familiar o alguien que le haga la traducción durante su comparecencia a la audiencia. Un menor de edad no puede ser intérprete. La Ciudad de Doral NO suministra servicio de traducción durante ningún procedimiento o durante el proceso de solicitudes de zonificación.

Connie Diaz, CMC City Clerk City of Doral 5/10

17-07/0000221612M

Alexion Raided by Brazilian Police in Sales Practices Probe



KRISTOFFER TRIPPLAAR/ASSOCIATED PRESS

Brazil's police are investigating whether Alexion, with help from a local patient association, subsidized lawsuits for patients to get access to the company's lead drug Soliris through the national health system.

by Mario Sergio Lima and Doni Bloomfield

Alexion Pharmaceuticals Inc.'s Sao Paulo offices were raided by Brazilian authorities Monday as part of an investigation into the drugmaker's sales practices, according to the country's national police.

Brazil's police are investigating whether Alexion, with help from a local patient association, subsidized lawsuits for patients to get access to the company's lead drug Soliris through the national health system, according to a request for a search warrant reviewed by Bloomberg. Law enforcement officials have found evidence that some of the lawsuits were fraudulent, according to the request, and used alleged fake diagnoses and a partnership between Alexion and the association to attract potential patients.

"Alexion provides support to the patient association in Brazil in the form of unrestricted educational grants and in accordance with local laws and regulations and industry code," Alexion spokeswoman Kim Diamond said by email. "Alexion has not been charged with any criminal or civil misconduct at this time" and is cooperating with the authorities.

The shares fell 3.4 percent to \$124.48 at the close, the biggest decline in almost four months.

Soliris, a blockbuster for two very rare blood conditions, accounted for more than 90 percent of Alexion's revenue last year.

More than 900 lawsuits were filed by lawyers from the Brazilian patient association to get Soliris paid for in the last six years. Patient lawsuits helped Alexion bring in \$400 million from the Brazilian government in the last six years, according to the search warrant request. Brazil accounted for about 5 percent of 2016 sales from Soliris, according to Geoff Meacham, an analyst with Barclays Plc.

"Patients in Brazil obtain access to Soliris through the judicial system since this is one of the few ways, and often the only way, that citizens in Brazil with a devastating disease can have access to available therapies and health-care services," Diamond, the company spokeswoman, said in the email. "Patients are exercising their constitutional right and they bring forth the legal proceedings in their own names in coordination with the patient advocacy organization."

Police also searched a local patient association, the Associacao dos Familiares, Amigos e Portadores de Doenças Graves, or AFAG, to which Alexion has said it's given financial support. The patient group's president, Maria Cecilia Oliveira, confirmed the search, and said in a telephone interview that the group is cooperating and has done nothing wrong. AFAG is based in Campinas, Brazil, about 60 miles northwest of Sao Paulo.

TURBULENT YEAR

Alexion's stock has had a turbulent year. Last November, the company announced it was investigating internal allegations of improper sales practices. The following month, its chief executive and chief financial officers resigned after losing the board's confidence because of information uncovered in that investigation, a person familiar with the matter said at the time.

In January, the drugmaker said its internal probe had found that senior managers had improperly applied pressure on employees to get some customers to expedite Soliris orders. In March, the company said its founder and chairman of the board, Leonard Bell, will retire, and the chief compliance officer stepped down.

In addition, Alexion is under investigation by the U.S. Securities and Exchange Commission and Department of Justice for issues related to the Foreign Corrupt Practices Act in countries including Brazil, according to company filings.

Mario Sergio Lima and Doni Bloomfield report for Bloomberg News.